相互作用
Nivolumab + Ponesimod
重症度: 中等度
Nivolumab and Ponesimod: moderate interaction.
最終更新日
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
概要
Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
この相互作用をわかりやすく説明すると
Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Nivolumab belongs to Oncology; Ponesimod belongs to Central Nervous System.
なぜ起こるのか
Ponesimod sequesters lymphocytes in lymphoid tissue via S1P receptor modulation, which may counteract the T-cell activation sought with PD-1 blockade.
対処法
Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
薬剤師に尋ねること
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、NivolumabとPonesimodの臨床対応の詳細なアドバイス、追加の注記、エビデンスの詳細、処方全体を対象とした相互作用チェッカーを利用できます。
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
WebでPro+を7日間無料でお試し。カード登録不要。
Nivolumabのその他の相互作用
Ponesimodのその他の相互作用
よくある質問
Can I take Nivolumab with Ponesimod?
MediHelp rates the interaction as moderate. Nivolumab and Ponesimod can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Ponesimod reduces circulating lymphocytes, while nivolumab alters immune regulation and can cause immune-related adverse events that are often treated with immunosuppression. Together they may make immune responses unpredictable and could raise infection risk or blunt antitumor immunity. Clinical data on the combination are limited.
How serious is the interaction between Nivolumab and Ponesimod?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting ponesimod during checkpoint inhibitor therapy unless clearly needed. If combined, monitor for infections and lymphocyte counts and reassess the oncologic benefit.
What other medicines interact with Nivolumab?
MediHelp also lists interactions of Nivolumab with, for example, Thalidomide, Dexamethasone-tobramycin, Dexamethasone. The full list is on the Nivolumab page.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。
